ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2014
Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles).
Article in Journal of immunotherapy (Hagerstown, Md. : 1997), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03057340 (The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities.Vaccines · 2025Review
- Targeting Cancer: Microenvironment and Immunotherapy Innovations.International journal of molecular sciences · 2024Review
- Cancer Vaccines: From the State of the Art to the Most Promising Frontiers in the Treatment of Colorectal Cancer.Pharmaceutics · 2023Review
- Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy.Pharmacological reviews · 2022Review
- Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors.International journal of molecular sciences · 2021Review
- Inflammation and tumor progression: signaling pathways and targeted intervention.Signal transduction and targeted therapy · 2021Article
- Tumor-Derived Autophagosomes (DRibbles) Activate Human B Cells to Induce Efficient Antigen-Specific Human Memory T-Cell Responses.Frontiers in immunology · 2021Article
- Prevalence and Spectrum of Predisposition Genes With Germline Mutations Among Chinese Patients With Bowel Cancer.Frontiers in genetics · 2021Article
- Regulatory B cells in cancer.Immunological reviews · 2021Review
- Interactions between tumor mutation burden and immune infiltration in ovarian cancer.International journal of clinical and experimental pathology · 2020Article
- Anti-Tumor Efficacy of an Adjuvant Built-In Nanovaccine Based on Ubiquitinated Proteins from Tumor Cells.International journal of nanomedicine · 2020Article
- Duality of B Cell-CXCL13 Axis in Tumor Immunology.Frontiers in immunology · 2020Review
- Review
- B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses.PloS one · 2018Article
- Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells.International journal of nanomedicine · 2018Article
- Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignancies.Oncotarget · 2017Review
- Autophagy Proteins in Phagocyte Endocytosis and Exocytosis.Frontiers in immunology · 2017Review
- Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy.Oncotarget · 2016Article
- From Antigen Delivery System to Adjuvanticy: The Board Application of Nanoparticles in Vaccinology.Vaccines · 2015Review
- Ubiquitinated proteins enriched from tumor cells by a ubiquitin binding protein Vx3(A7) as a potent cancer vaccine.Journal of experimental & clinical cancer research : CR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-derived autophagosomes (DRibble) selectively capture tumor-specific antigens and induce a dramatic T-cell activation and expansion when injected into lymph nodes of naive mice. Both dendritic and B cells can efficiently cross-prime antigen-specific T cells. In this report, we demonstrated that a booster vaccination with naive B cells loaded with DRibbles eradicated E.G7-OVA tumors in mice that were previously treated with adoptive transfer naive OT-I T cells and intranodal immunization with DRibbles derived from E.G7 tumors. The antitumor efficacy was accompanied by a heighten number of tumor-specific interferon-γ-producing T cells and antibodies. However, the same treatment in the absence of adoptive T-cell transfer exhibited a limited efficacy. In contrast, when DRibble-loaded B cells were activated with CpG and anti-CD40 antibody before use as booster vaccines, established E.G7 tumors were completely eradicated in the absence of T-cell transfer. Therefore, our results document that B cells could efficiently cross-present tumor-specific antigens captured by DRibbles and suggest that naive B cells can be deployed as an effective and readily accessible source of antigen-presenting cells for cancer immunotherapy clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.